Covered recipient · General Payments record
ARIARATNAM GOBIKRISHNA
General Payments · PY2018–2024
$7,994.90
- Reported across 148 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,024.23 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $388.91 | 5 |
| Novo Nordisk AS | $219.97 | 6 |
| Abbott Laboratories | $128.53 | 1 |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $124.98 | 1 |
| PFIZER INC. | $20.27 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $128.53 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125374663 | CMS |
| Amgen Inc. | $32.50 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111584999 | CMS |
| Amgen Inc. | $150.00 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111585001 | CMS |
| Amgen Inc. | $150.00 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111585005 | CMS |
| Amgen Inc. | $23.08 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111585003 | CMS |
| Amgen Inc. | $33.33 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111585007 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $124.98 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086152117 | CMS |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101410855 | CMS |
| Novartis Pharmaceuticals Corporation | $16.57 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086893313 | CMS |
| Novo Nordisk Inc | $19.63 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108576555 | CMS |
| Novo Nordisk Inc | $18.98 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108577433 | CMS |
| Novo Nordisk Inc | $20.14 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108575160 | CMS |
| Novo Nordisk Inc | $18.33 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108579227 | CMS |
| Novo Nordisk Inc | $124.44 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108576865 | CMS |
| Novo Nordisk Inc | $18.45 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108574704 | CMS |
| PFIZER INC. | $20.27 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131089421 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.